Evidence map›Paper›PMID 39852655›Full record

ArticleTropical medicine and infectious disease2024

Safety and Efficacy of Incorporating Actellic

Tonny Jimmy Owalla, Emmanuel Okurut, Kenneth Ssaka, Gonsaga Apungia, Barbara Cemeri, Andrew Akileng, Basil Ojakol, Mark J I Paine, Hanafy M Ismail, Thomas G Egwang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tropical medicine and infectious disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tonny Jimmy OwallaMed Biotech Laboratories, Kampala P.O. Box 9364, Uganda.
Emmanuel OkurutMed Biotech Laboratories, Kampala P.O. Box 9364, Uganda.ORCID 0000-0002-1482-4532
Kenneth SsakaDepartment of Community Health, Kiryandongo General Hospital, Kiryandongo P.O. Box 351620, Uganda.
Gonsaga ApungiaMed Biotech Laboratories, Kampala P.O. Box 9364, Uganda.
Barbara CemeriMed Biotech Laboratories, Kampala P.O. Box 9364, Uganda.
Andrew AkilengMed Biotech Laboratories, Kampala P.O. Box 9364, Uganda.ORCID 0009-0001-1091-0812
Basil OjakolMed Biotech Laboratories, Kampala P.O. Box 9364, Uganda.
Mark J I PaineDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.
Hanafy M IsmailDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.ORCID 0000-0002-9953-9588
Thomas G EgwangMed Biotech Laboratories, Kampala P.O. Box 9364, Uganda.

Funding

Grand Challenges Canada NA
6 · The paper itself

Abstract

Indoor residual spraying (IRS) and the use of insecticide-treated bednets for malaria vector control have contributed substantially to a reduction in malaria disease burden. However, these control tools have important shortcomings including being donor-dependent, expensive, and often failing because of insufficient uptake. We assessed the safety and efficacy of a user-friendly, locally tailored malaria vector control approach dubbed "Hut Decoration for Malaria Control" (HD4MC) based on the incorporation of a WHO-approved insecticide, Actellic

Indexed as

Actellic® 300 CSefficacy: pirimiphos-methyl CSHD4MChouse decoration for malaria controlIRSmalariaorganophosphatesafetyvectors

Identifiers

PMID39852655
PMCPMC11768474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.